Takeda Pharmaceutical Company Limited (F:TKDA) — Market Cap & Net Worth
Market Cap & Net Worth: Takeda Pharmaceutical Company Limited (TKDA)
Takeda Pharmaceutical Company Limited (F:TKDA) has a market capitalization of $43.60 Billion (€37.29 Billion) as of July 23, 2026. Listed on the F stock exchange, this Germany-based company holds position #622 globally and #127 in its home market, demonstrating a 0.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Takeda Pharmaceutical Company Limited's stock price €14.80 by its total outstanding shares 3159192822 (3.16 Billion). See how much does Takeda Pharmaceutical Company Limited reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Takeda Pharmaceutical Company Limited Market Cap History: 2019 to 2026
Takeda Pharmaceutical Company Limited's market capitalization history from 2019 to 2026. Data shows growth from $52.36 Billion to $54.66 Billion (1.64% CAGR).
Takeda Pharmaceutical Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Takeda Pharmaceutical Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Takeda Pharmaceutical Company Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.45x
Takeda Pharmaceutical Company Limited's market cap is 0.45 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $52.36 Billion | $2.10 Trillion | $109.13 Billion | 0.02x | 0.48x |
| 2020 | $46.15 Billion | $3.29 Trillion | $44.24 Billion | 0.01x | 1.04x |
| 2021 | $39.47 Billion | $3.20 Trillion | $376.00 Billion | 0.01x | 0.10x |
| 2022 | $49.81 Billion | $3.57 Trillion | $230.06 Billion | 0.01x | 0.22x |
| 2023 | $45.47 Billion | $4.03 Trillion | $317.02 Billion | 0.01x | 0.14x |
| 2024 | $46.17 Billion | $4.26 Trillion | $144.07 Billion | 0.01x | 0.32x |
| 2025 | $48.75 Billion | $4.58 Trillion | $107.93 Billion | 0.01x | 0.45x |
Competitor Companies of TKDA by Market Capitalization
Companies near Takeda Pharmaceutical Company Limited in the global market cap rankings as of July 23, 2026.
Key companies related to Takeda Pharmaceutical Company Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #507 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #523 globally with a market cap of $51.27 Billion USD ( CN¥350.40 Billion CNY).
- Haleon plc (NYSE:HLN): Ranked #668 globally with a market cap of $40.34 Billion USD.
- Galderma Group N (SW:GALD): Ranked #736 globally with a market cap of $37.01 Billion USD ( CHF29.28 Billion CHF).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #507 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #523 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $51.27 Billion | CN¥54.93 |
| #668 | Haleon plc | NYSE:HLN | $40.34 Billion | $9.92 |
| #736 | Galderma Group N | SW:GALD | $37.01 Billion | CHF175.00 |
Takeda Pharmaceutical Company Limited Historical Marketcap From 2019 to 2026
Between 2019 and today, Takeda Pharmaceutical Company Limited's market cap moved from $52.36 Billion to $ 54.66 Billion, with a yearly change of 1.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €54.66 Billion | +12.12% |
| 2025 | €48.75 Billion | +5.60% |
| 2024 | €46.17 Billion | +1.52% |
| 2023 | €45.47 Billion | -8.70% |
| 2022 | €49.81 Billion | +26.18% |
| 2021 | €39.47 Billion | -14.46% |
| 2020 | €46.15 Billion | -11.87% |
| 2019 | €52.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 22nd, 2026 the market cap of Takeda Pharmaceutical Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.60 Billion USD |
| MoneyControl | $43.60 Billion USD |
| MarketWatch | $43.60 Billion USD |
| marketcap.company | $43.60 Billion USD |
| Reuters | $43.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more